JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

Generic Medicines as a Pillar of Sustainable Healthcare: Policies, Practices, and Progress

Neha Ashish Tiwari, Research Scholar: Pillai College of Arts, Commerce and Science, New Panvel,

Abstract

Generic medicines play an essential role in creating affordable and accessible healthcare systems. This study explores their significance in sustainable healthcare through the lens of policies, practices, and progress. A comprehensive analysis of the regulatory frameworks demonstrates how policies fostering the development and adoption of generics lead to cost savings without compromising safety or efficacy

Key Aspects: The literature review highlights key areas an introduction to generic medicines, their contribution to sustainable healthcare, and policies promoting their adoption.

Research Problem: The research investigates several problems, including consumer awareness, healthcare provider support, regulatory challenges, and market dynamics in generic medicine adoption.

Hypothesis: There is a positive impact of Generic medicine on healthcare providers and patients of the benefits, safety and cost-effectiveness of adoption of a sustainable healthcare system.

Methodology: The research uses primary and secondary data to examine public and professional perceptions of generic medicines. However, limited participant availability for interviews constrains data diversity.

Findings: It reveals consumer trust, cost-effectiveness, and supportive policies as drivers for generics, while misconceptions about their efficacy and quality remain barriers.

Result: This research underscores the need for awareness campaigns and policy advancements to realize the full potential of generic medicines in sustainable healthcare.

Keywords: Generic Medicine, Sustainable Healthcare, Policy Analysis, Regulatory Challenges

I.Introduction

The increasing cost of healthcare and the global demand for more accessible and affordable medicines have made the issue of sustainability in healthcare systems a critical concern worldwide. As nations strive to meet the health needs of their populations, especially in the face of chronic diseases, ageing populations, and limited resources, one solution has emerged as a key enabler of sustainable healthcare: generic medicines. Generic medicines are pharmaceutical products that are equivalent to branded medications in terms of dosage, strength,

administration, and intended use but are marketed at a significantly lower price due to the absence of brand-name costs, including marketing and research expenses.

Generics offer a pragmatic approach to managing the escalating costs of healthcare, especially in developing economies where access to life-saving medications is limited by high drug prices. They play a pivotal role in expanding access to essential treatments, improving health outcomes, and alleviating the financial burden on both individuals and healthcare systems. As such, they are not only central to the economic sustainability of healthcare systems but also critical to achieving universal health coverage (UHC), a goal set by the World Health Organization (WHO) for ensuring equitable access to essential health services for all, without financial hardship. Despite their significant advantages, generic medicines face several challenges in terms of public perception, regulatory frameworks, and market dynamics. While many countries have embraced generics as a cost-saving measure, barriers still exist in terms of consumer confidence, quality concerns, and inadequate policies to promote their use. For generic medicines to realize their full potential as a cornerstone of sustainable healthcare, it is crucial to understand the policies, practices, and progress that have shaped their role in various healthcare systems across the globe.

This research aims to explore the integration of generic medicines into national healthcare systems, focusing on the policies and regulations that support their use, the practices that promote their adoption, and the progress made in addressing the challenges to their widespread acceptance. By examining the role of generic medicines through this lens, this paper seeks to provide insights into how generics can contribute to the long-term sustainability of healthcare, improving access to affordable treatment and ultimately fostering healthier societies.

II. Need of the Study

The need of the study on Generic Medicines as a Pillar of Sustainable Healthcare: Policies, Practices, and Progress addressed the following key needs:

Rising Healthcare Costs: The escalating cost of healthcare, driven by expensive brand-name medicines, poses a significant burden on healthcare systems worldwide, particularly in low- and middle-income countries. Generic medicines offer an affordable alternative, making healthcare more accessible and sustainable.

Access to Essential Medicines: Generic medicines play a critical role in improving access to life-saving treatments, especially in regions where high drug prices prevent many individuals from obtaining necessary medications.

Economic Sustainability: Generic medicines offer a cost-effective solution to reduce healthcare expenditures, enabling health systems to allocate resources more effectively. This research explores the economic impact of generics and their role in achieving long-term sustainability in healthcare.

Policy and Practice Gaps: While some countries have successfully integrated generics into their healthcare systems, others face challenges due to inadequate policies and ineffective healthcare practices. This study

highlights the need for evidence-based policy recommendations to enhance the role of generics in global healthcare systems.

Contribution to Sustainable Healthcare: The study is essential to understand how generic medicines can serve as a key pillar in building sustainable healthcare systems by reducing costs, improving access to medicines, and supporting the achievement of health-related Sustainable Development Goals (SDGs).

Bridging the Knowledge Gap: While there is substantial research on the benefits of generic medicines, there remains a gap in understanding how policy, practice, and progress intersect to create an enabling environment for generics. This study aims to bridge that gap and provide insights for policymakers and healthcare stakeholders.

III Scope of the Study

The scope of the study will include the following dimensions:

Healthcare System Integration: The study will assess how generic medicines are integrated into healthcare systems, including their availability in public and private healthcare settings, and the role of national health insurance programs in promoting their use.

Economic Impact: The research will evaluate the economic effects of generic medicines on healthcare costs, exploring their contribution to reducing overall healthcare expenditures, improving the affordability of treatment, and supporting financial sustainability in healthcare systems.

Barriers and Challenges: The study will identify and analyse the barriers to the adoption and widespread use of generic medicines, such as public misconceptions, quality concerns, regulatory hurdles, and challenges posed by patenting practices and the pharmaceutical market structure.

Patient and Provider Perspectives: The research will include an examination of the perspectives of healthcare providers and patients, focusing on their trust in generics, knowledge of their benefits, and factors influencing the decision to prescribe or use generic medicines.

Sustainable Development Goals (SDGs): The study will explore how generic medicines contribute to achieving the Sustainable Development Goals (SDGs), particularly Goal 3 (Good Health and Well-being), by improving access to affordable medicines and promoting healthcare equity.

Healthcare Cost Savings and Quality of Care: The study will assess the balance between cost savings and the quality of care when using generic medicines, focusing on how healthcare systems can ensure that the use of generics does not compromise treatment outcomes.

Future Directions and Policy Recommendations: The research will provide insights into future trends in the pharmaceutical market, potential improvements in policy, and strategies to further enhance the role of generic medicines in sustainable healthcare.

IV Literature Review

Pantoja, et.al (2022)."Pharmaceutical Policies: Effects of Regulating Drug Insurance Schemes" The paper gives an insightful and well-researched contribution to the field of healthcare policy. It effectively dissects the intricate dynamics between drug insurance regulation and pharmaceutical market outcomes. Though there are areas for improvement, particularly regarding long-term impact analysis and geographic diversity, the paper is a valuable resource for anyone interested in understanding the nuances of pharmaceutical regulation and its implications for global health policy. The study is a key reference for researchers, policymakers, and healthcare economists looking to improve drug access and affordability while maintaining system sustainability.

Dylst, et al (2013). "Generic Medicines: Solutions for a Sustainable Drug Market" contributed in his paper significantly to the literature on pharmaceutical economics and policy by providing a comprehensive review of the factors influencing the generic drug market. Their analysis integrates economic, regulatory, and healthcare perspectives, offering a multidimensional understanding of the challenges and opportunities in promoting generics. The author's study highlights the potential of generics as a tool for controlling drug costs and improving access to essential medicines, making a valuable contribution to the ongoing debate on sustainable healthcare financing.

Priyadarsini et.al. (2023) "A comparative study on perception and use of generic drugs between public and private health practitioners" studied five countries and found significant variations in patient perceptions and preferences towards generic medicines. While some countries showed higher acceptance and positive attitudes towards generics, others displayed considerable scepticism and a strong preference for branded drugs. The Study found cultural factors, such as trust in the healthcare system and prior experiences with medications, played a significant role in shaping these attitudes also the educational interventions were generally effective in improving perceptions of generic medicines, but the degree of effectiveness varied by country. Further, Patients in countries with higher initial scepticism showed the most significant improvement post-intervention. The paper included a structured questionnaire of 500 participants, assessing their knowledge, attitudes, and preferences regarding generic medicines. The research included in-depth interviews with 50 participants from different countries to explore the underlying reasons for their perceptions and preferences in greater detail. The study found that generics are cost-efficient options for patients, but this benefit does not always convert a patient into a consumer. We found that awareness is the only factor that translates a patient into a consumer of generic medicines. The study will be useful for this research paper.

V Objectives: - 1. To examine the role of generic medicines in reducing healthcare costs.

2. To explore the challenges and opportunities in the adoption of generics.

VI Hypothesis:

H1: There is a positive impact of Generic medicine on healthcare providers and patients of the benefits, safety and cost-effectiveness of adoption of a sustainable healthcare system

VII Research methodology:

This study adopts a descriptive and analytical research design, utilizing secondary data to investigate the role of generic medicines as a pillar of sustainable healthcare. By examining policy frameworks, practices, and progress across global and regional contexts, the research aims to offer insights into how generic medicines contribute to affordability, accessibility, and long-term healthcare sustainability.

1. Sources of Secondary Data: - The research relies exclusively on secondary data sourced from reputable and relevant materials such as:

2. Government and Regulatory Reports: Policies and regulations from health ministries, the World Health Organization (WHO), and other regulatory bodies, Data from market research firms and pharmaceutical industry stakeholders, including reports from IMS Health and other agencies analysing generic drug trends.

3. Academic Journals and Books: Peer-reviewed articles, systematic reviews, and books addressing the impact of generic medicines on healthcare systems.

4. Healthcare Organization Databases: Public datasets from the WHO, OECD, and national health authorities, which provide quantitative information on healthcare expenditure, drug utilization rates, and cost savings.

We have studied the governmental policies that have driven the promotion of generic medicines and highlight success stories showcasing effective implementation across various regions as follows:

1. Policy Framework Development

National Generic Medicine Policies: (1) Establishment of comprehensive policies to mandate and promote the use of generic medicines in healthcare systems. (2) Inclusion of generics in essential medicines lists for public health programs.

Pricing Regulations: (1) Implementation of price caps to make generic medicines affordable.

(2) Regular monitoring and evaluation of price control mechanisms.

Incentives for Manufacturers: (1) Subsidies and tax exemptions for generic medicine producers. (2) Support for R&D in generic pharmaceuticals.

Procurement Policies: Government bulk procurement of generic medicines to supply public healthcare facilities. Transparent and competitive tendering processes.

Legislation and Legal Frameworks Patents and Intellectual Property (IP) regulations facilitating timely entry of generics post-patent expiry. Policies mandating bioequivalence studies to ensure the efficacy and safety of generics.

Awareness Campaigns: Nationwide campaigns to educate the public and healthcare professionals on the efficacy and safety of generic medicines. **(2)** Collaboration with civil society organizations for advocacy and outreach.

Strengthening Distribution Channels (1) Expansion of supply chain infrastructure to ensure the availability of generics in rural and underserved areas. **(2)** Development of online platforms for generic drug availability and price comparison.

Jan Aushadhi Scheme - Implementation Success Stories India

Policy Action: The Pradhan Mantri Bhartiya Aushadhi Pari Yojana started (PMBJP) to provide quality generic medicines at affordable prices. Over 9,000 retail outlets (Jan Aushadhi Kendra's) established across the country. Availability of more than 1,700 generic drug formulations for chronic and acute conditions. Which helps to increase substantial cost savings for patients on chronic medications. **Impact:** Savings of 50%–90% on medicines for patients. Over ₹15,000 crore is saved annually for Indian households. Improved accessibility to essential medicines, particularly in rural and underserved areas.

Brazil – Pharmacia Popular Program: Public-private partnership model to distribute generics via accredited pharmacies. **It is** Free or highly subsidized medications for chronic diseases like hypertension and diabetes. Coverage expanded to over 80% of the population.

Thailand – Universal Health Coverage Scheme: Mandatory prescription of generics in public hospitals under the Universal Coverage Scheme. **Found**: Dramatic reduction in out-of-pocket expenses for patients. Significant improvements in access to essential medicines.

United States – Generic Drug User Fee Amendments (GDUFA): Strengthened the U.S. FDA's ability to review and approve generic medicines efficiently. **Resulted in** Accelerated approval timelines for generic drugs. Increased competition in the pharmaceutical market, lowering drug prices.

South Africa – Antiretroviral (ARV) Program: Procurement of generic ARVs for HIV treatment under public health programs. **Benefited that** Cost reductions by up to 80% compared to branded drugs. Largest publicly funded ARV program globally, benefiting millions of patients.

European Union – Generic Medicines Policy: Harmonized regulations for bioequivalence testing across member states**. Diagnosed that** Robust market competition leads to substantial cost savings for healthcare systems.

Bangladesh – Pharmaceutical Export Policy: Support for domestic manufacturing of generics through local industry protections and export incentives. Rapid growth in generic medicine exports contributes to global healthcare affordability.

Success Stories of Generic Medicine Implementation in India

India has emerged as a global leader in producing and adopting generic medicines, driven by effective policies and innovative initiatives. The success stories demonstrating the role of generic medicine in fostering sustainable healthcare in the country are as follows.

Introduction of the Drug Price Control Order (DPCO) Objective: To regulate the prices of essential medicines and ensure affordability. **Implementation:** The National Pharmaceutical Pricing Authority (NPPA) enforces ceiling prices for essential drugs, many of which are generics.

Regular updates to the National List of Essential Medicines (NLEM). Impact: Over 850 essential drugs were brought under price control. Significant reduction in costs for treatments like diabetes, hypertension, and cancer.

Expansion of Generic ARVs for HIV/AIDS Treatment: The Objective: To ensure affordable and universal access to antiretroviral (ARV) drugs for HIV/AIDS patients. **Implementation:** Collaboration with the National AIDS Control Organization (NACO). Generics manufactured by Indian pharmaceutical companies like Cipla are supplied domestically and internationally. **Impact:** Over 1.5 million HIV patients in India receive free ARV treatment. India became the world's largest supplier of affordable ARVs, saving millions of lives globally.

Government Procurement for Public Health Programs

Objective: To procure affordable generic medicines for national health programs like the National Health Mission (NHM). **Implementation:** Centralized procurement of generics for diseases such as tuberculosis, malaria, and cardiovascular disorders. Founded that Distribution through public healthcare facilities and mobile medical units. **Impact:** Reduced treatment costs for millions of beneficiaries. Increased medication adherence due to affordability**.**

Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (PMJAY)

Objective: To provide cashless and paperless access to essential healthcare, including medicines, for low-income families. **Implementation:** Integration of generic medicines in treatment protocols under the PMJAY scheme. Partnerships with generic manufacturers to supply medicines to empanelled hospitals. **Impact:** Over 500 million beneficiaries access affordable medicines and treatments. Reduction in catastrophic healthcare expenditures among economically disadvantaged families.

State-Level Initiatives

Tamil Nadu Medical Services Corporation (TNMSC): A centralized system for procurement and distribution of generic medicines in government hospitals. This resulted in an uninterrupted supply of quality drugs at lower costs.

Rajasthan's Free Medicine Scheme: Provision of free generic medicines in public healthcare centres since 2011. Benefitted over 90 million people, with savings of ₹300 crore annually.

Growth of the Indian Generic Pharma Industry

Objective: To establish India as a global hub for generic medicine production. **Implementation:** Policies encouraging generic drug exports and investments in pharmaceutical manufacturing. India supplies over 40% of the generic medicines consumed in the United States. **Impact:** Significant reduction in global drug costs

for life-threatening diseases like cancer and hepatitis C. Generics account for over 70% of medicines consumed in India.

Health Awareness and Advocacy Campaigns

Objective: To enhance public trust in generic medicines**. Implementation:** Campaigns like "Jan Aushadhi Mitra" to educate citizens about the efficacy and affordability of generics. Training programs for doctors and pharmacists to promote generic prescribing. **Impact:** Increased prescription of generics in public and private healthcare settings. Greater acceptance of generics among patients, leading to improved healthcare equity.

Government Policies Key Objectives in Promoting Generic Medicines

To establish generic medicines as a pillar of sustainable healthcare, governments have implemented targeted measures addressing cost reduction, consumer and healthcare provider attitudes, and the challenges and opportunities in adoption. Below is an examination of how government initiatives fulfil these objectives.

1. To Examine the Role of Generic Medicines in Reducing Healthcare Costs

Price Control Mechanisms:

Drug Price Control Order (DPCO): Caps prices of essential medicines, ensuring affordability. National Pharmaceutical Pricing Authority (NPPA): Monitors prices to prevent profiteering and ensure fair pricing for generics.

Government Procurement: Bulk purchasing of generics for public healthcare systems reduces costs for patients and taxpayers. Example: Under the Jan Aushadhi Scheme, patients save 50%–90% on medicines.

Subsidies and Financial Support: Tax exemptions and incentives for generic manufacturers to reduce production costs. Partnerships with public health programs to integrate affordable generics into treatment packages.

Impact Studies: Periodic evaluations by health and finance ministries demonstrate significant reductions in out-of-pocket expenditures for households using generics.

2. To Assess Consumer and Healthcare Provider Attitudes Towards Generic Medicines

Awareness Campaigns: Public campaigns educate consumers on the safety, efficacy, and cost benefits of generic medicines. Jan Aushadhi Diwas promotes trust and awareness of generics nationwide.

Professional Training Programs: Workshops and training sessions for healthcare providers encourage generic prescribing. Inclusion of generic medicine topics in medical education curricula to address misconceptions.

Consumer Engagement: Feedback mechanisms at Jan Aushadhi Kendra's and public healthcare facilities to understand consumer concerns. Surveys and studies conducted by health ministries to assess public attitudes and improve policy outreach.

Legislative Support: Regulations mandating doctors to prescribe generic names of drugs rather than brand names. Stringent bioequivalence testing requirements to assure consumers and providers of quality.

3. To Explore Challenges and Opportunities in the Adoption of Generics

Quality Perception: Government certifications and bioequivalence standards ensure generic medicines meet international quality benchmarks. Transparency initiatives, such as publishing generics' quality assessment reports, build public trust.

Supply Chain Issues: Strengthening rural distribution networks and logistics to ensure availability. Collaboration with state governments to implement local-level generic medicine schemes.

Market Penetration: Providing financial incentives to retailers and wholesalers to stock generics. E-pharmacies promoting online availability of affordable generics.

Opportunities Harnessed:

Domestic Pharmaceutical Growth: Policies supporting the "Make in India" initiative boost local manufacturing of generics. Subsidized loans and grants for pharmaceutical R&D enhance competitiveness in the global market.

Global Leadership: Leveraging India's role as the "pharmacy of the world" by expanding generic exports to developing countries. Strategic partnerships with global health organizations to supply affordable generics for diseases like HIV, tuberculosis, and malaria.

Technological Integration: Digital platforms for monitoring generic medicine prescriptions and availability. Telemedicine services incorporating generic drug recommendations to expand outreach.

Summary of Government's Role in Fulfilling Objectives

Reducing Healthcare Costs: Governments leverage price control, bulk procurement, and subsidy programs to make generics cost-effective for patients and healthcare systems.

Shaping Attitudes: Consumer and provider attitudes are addressed through awareness campaigns, professional training, and strict quality regulations that instil confidence in generics.

Overcoming Challenges and Leveraging Opportunities: Challenges such as quality perceptions and supply chain issues are countered with robust policies, while opportunities in domestic manufacturing and global export markets are actively pursued. These efforts collectively demonstrate how government actions align with the objectives of reducing healthcare costs, enhancing trust, and fostering the adoption of generic medicines as a cornerstone of sustainable healthcare.

Conclusion and Findings Generic medicines have emerged as a critical pillar of sustainable healthcare, offering a pathway to equitable, affordable, and accessible healthcare systems globally. This research underscores the transformative role of generic medicines in reducing healthcare costs, improving public health outcomes, and fostering economic sustainability. The key Findings are as follows:

1. Impact on Healthcare Costs

Generic medicines significantly reduce out-of-pocket expenditures for patients, often by 50%–90% compared to branded alternatives. Price control mechanisms, bulk procurement by governments, and integration of generics into public health programs have amplified cost savings, making healthcare more affordable for low- and middle-income populations.

2. Policy Effectiveness

Policies like the Drug Price Control Order (DPCO) and initiatives such as Pradhan Mantri Bhartiya Jan Aushadhi Pari Yojana (PMBJP) have played pivotal roles in enhancing the availability and affordability of generics. Countries with strong legislative frameworks and robust supply chain systems demonstrate higher adoption rates of generics and greater public trust in their efficacy.

3. Consumer and Provider Attitudes

While consumer acceptance of generic medicines has grown due to awareness campaigns and cost benefits, misconceptions about their quality persist in some segments. Healthcare providers are more likely to prescribe generics when assured of their bioequivalence and quality, underscoring the importance of stringent regulatory frameworks.

In the Global Leadership and Opportunities Scenario

India has established itself as a global leader in generic medicine production, contributing significantly to international healthcare programs like HIV treatment through affordable antiretroviral drugs. The “Make in India” initiative and export-friendly policies have positioned India as the "pharmacy of the world," creating opportunities for economic growth while addressing global healthcare challenges.

Challenges in Adoption Perceived quality issues, supply chain limitations, and resistance from brand-centric pharmaceutical markets remain barriers to widespread generic adoption. Addressing these challenges requires continued investment in quality assurance, public education, and infrastructure development.

Conclusion

Generic medicines are not only a cost-effective alternative but also a cornerstone for achieving sustainable healthcare systems. By reducing the financial burden on individuals and governments, generics enable broader access to essential medicines and improve health equity. Government initiatives, combined with industry innovations, have demonstrated the feasibility of scaling generic medicine adoption while ensuring quality and accessibility. However, sustained progress requires a multi-faceted approach that includes policy refinement, enhanced public-private collaboration, and global partnerships.

The findings of this research reaffirm the critical role of generic medicines in addressing the healthcare needs of growing populations, particularly in resource-constrained settings. As nations strive to achieve universal health coverage and sustainable development goals (SDGs), generics will continue to serve as a vital tool in bridging healthcare gaps and fostering resilient health systems.

References

- National Pharmaceutical Pricing Authority (NPPA), India: Available at: https://nppaindia.nic.in
- World Health Organization (WHO) Accessed from: https://www.who.int
- Pradhan Mantri Bhartiya Jan Aushadhi Pari Yojana (PMBJP), India Website: https://janaushadhi.gov.in
- U.S. Food and Drug Administration (FDA) Reference link: https://www.fda.gov
- European Medicines Agency (EMA) Retrieved from: https://www.ema.europa.eu
- Ministry of Health and Family Welfare, India: Official site: https://www.mohfw.gov.in
- Trade-Related Aspects of Intellectual Property Rights (TRIPS): Document available at: https://www.wto.org
- Pharmaceutical Export Promotion Council of India (Pharmexcil): Source: https://www.pharmexcil.com
- World Trade Organization (WTO) Link: https://www.wto.org
- Pantoja, T., Peñaloza, B., Cid, C., Herrera, C. A., Ramsay, C. R., & Hudson, J. (2022). Pharmaceutical policies: effects of regulating drug insurance schemes. The Cochrane Database of Systematic Reviews, 5(5), CD011703.https://doi.org/10.1002/14651858.CD011703.pub2
- Dylst, P., Vulto, A., Godman, B., & Simoens, S. (2013). Generic medicines: solutions for a sustainable drug market?. *Applied health economics and health policy*, *11*(5), 437–443. https://doi.org/10.1007/s40258-013-0043-z
- Priyadarsini, R., Maheswari, Y. N., Prabha, M. L., & Ramya, J. E. (2023). A comparative study on perception and use of generic drugs between public and private health practitioners. Journal of family medicine and primary care, 12(12), 3222–3227. https://doi.org/10.4103/jfmpc.jfmpc_905_23